CTY

City Therapeutics Inc

20.83

Oct 20 • 4:00 PM ET -0.63 (-2.94%)

20.62

Aftermarket • 7:30 PM ET -0.21 (-1.01%)

Healthcare Biotechnology USA Small NASD

Oct 19, 4:05 PMCity Therapeutics closes its upsized Nasdaq IPO at $18 per share, raising $230 million in gross proceeds after underwriters fully exercise their overallotment option.

Peers: ARWR SLN WVE ALNY ABUS IONS DYN BLTE KRRO PRQR

| Held by: TDNA

Index	-
Market Cap	1.05B
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Oct 16, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	11.70%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.40%
SMA50	-3.40%
SMA200	-3.40%
Trades

Shs Outstand	50.33M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	23.88 -12.77%
52W Low	20.50 1.61%
Volatility	- -
ATR (14)	2.08
RSI (14)	-
Beta	-
Rel Volume	0.74
Avg Volume	854.40K
Volume	633,165

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-9.43%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	21.46
Price	20.83
Change %	-2.94%

Oct-19-26 04:01PM	City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-16-26 01:46PM	Another Biotech IPO Pops on Rough Day for Broader Market (Barrons.com)
01:39PM	City Therapeutics surges in market debut after upsizing $200M IPO (Investing.com)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARCH Venture Partners XII, LLC	10% Owner	Oct 19 '26	Buy	18.00	170,000	3,060,000	13,692,507	Oct 19 05:38 PM
NELSEN ROBERT	Director	Oct 19 '26	Buy	18.00	170,000	3,060,000	13,692,507	Oct 19 05:37 PM

City Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the development of RNAi therapeutics. The company was founded by John Maraganore, Sebastian Trousil, Ari Nowacek, Mark Keating, Kotaro Nakanishi, Yukihide Tomari, and Phillip Zamore on July 17, 2023 and is headquartered in Cambridge, MA.

Ph.D.Dr. John Michael Maraganore M.D.

PresidentDr. Andrew C. Orth M.B.A.

Chief Scientific OfficerDr. Tracy Zimmermann Ph.D.

Ph.D.Dr. Baisong Mei M.D.

M.D.Dr. Ari Nowacek M.B.A.

Open in Screener

PRME

Prime Medicine Inc

3.92

Oct 20 • 3:59 PM ET +0.09 (2.35%)

3.85

Aftermarket • 7:59 PM ET -0.07 (-1.79%)

Healthcare Biotechnology USA Small NASD

PRME Prime Medicine Inc daily Stock Chart

Peers: BEAM NTLA EDIT CRSP WVE DTIL KRRO SANA QURE RGNX

| Held by: ARKG XBI VTI IWM VXF IWO IBB SCHA VTWO IWC

Index	RUT
Market Cap	710.99M
Enterprise Value	728.40M
Income	-187.89M
Sales	4.07M
Book/sh	0.22
Cash/sh	0.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	146
IPO	Oct 20, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	174.69
P/B	17.80
P/C	7.48
P/FCF	-
EV/EBITDA	-
EV/Sales	178.97
Quick Ratio	3.05
Current Ratio	3.05
Debt/Eq	2.83
LT Debt/Eq	2.60
Option/Short	Yes / Yes

EPS (ttm)	-1.09
EPS next Y	-0.92
EPS next Q	-0.24
EPS this Y	28.53%
EPS next Y	4.16%
EPS next 5Y	13.58%
EPS past 3/5Y	2.55% -91.28%
Sales past 3/5Y	- -2.32%
EPS Y/Y TTM	32.10%
Sales Y/Y TTM	-17.90%
EPS Q/Q	41.64%
Sales Q/Q	3.50%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	6.69% -48.74%

Insider Own	46.28%
Insider Trans	0.00%
Inst Own	49.36%
Inst Trans	6.52%
ROA	-71.16%
ROE	-373.29%
ROIC	-131.10%
Gross Margin	-81.64%
Oper. Margin	-4824.94%
Profit Margin	-4613.11%
SMA20	16.74%
SMA50	16.58%
SMA200	12.62%
Trades

Shs Outstand	180.74M
Shs Float	97.44M
Short Float	32.96%
Short Ratio	9.23
Short Interest	32.12M
52W High	6.30 -37.78%
52W Low	2.67 46.82%
Volatility	10.04% 10.78%
ATR (14)	0.34
RSI (14)	58.60
Beta	2.33
Rel Volume	1.06
Avg Volume	3.48M
Volume	3,694,622

Perf Week	18.07%
Perf Month	22.88%
Perf Quarter	26.86%
Perf Half Y	2.89%
Perf YTD	12.97%
Perf Year	-36.57%
Perf 3Y	-45.10%
Perf 5Y	-
Perf 10Y	-
Recom	1.46
Target Price	7.33
Prev Close	3.83
Price	3.92
Change %	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-26	Resumed	Chardan Capital Markets	Buy	$7
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$9
Jun-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$8
Mar-12-26	Initiated	Oppenheimer	Outperform	$11
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27

Show Previous Ratings

Oct-05-26 08:00AM	Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease (GlobeNewswire) +7.72%
Sep-24-26 04:47PM	Prime Medicine stock surges on FDA IND clearance (Investing.com) -5.54%
04:01PM	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
08:46AM	Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
Sep-23-26 05:49PM	CRSP, NTLA, BEAM, PRME, EDIT Shares Slip Did Claude Just Spook Gene-Editing Stocks? (Stocktwits) -11.58%
08:00AM	Loading…
Aug-06-26 08:00AM	Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com)
Jul-23-26 04:05PM	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease (GlobeNewswire)
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com) -10.64%
Jul-08-26 04:10PM	Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle (Investor's Business Daily) +15.79% -8.44%
12:47PM	PRME Surges 15% After Winning Arbitration Against Beam Clears Path To Human Trials For Its Gene-Editing Drug (Stocktwits)
08:00AM	Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics (GlobeNewswire)
05:07AM	Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal (BioPharma Dive)
Jun-22-26 08:00AM	Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Jun-18-26 08:00AM	Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease (GlobeNewswire)
08:00AM	Loading…
Jun-03-26 08:00AM	Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-28-26 08:00AM	Prime Medicine to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-07-26 08:00AM	Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.65%
Apr-16-26 08:00AM	Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer (GlobeNewswire)
Mar-31-26 08:49PM	The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step (PR Newswire) +10.48%
Mar-24-26 10:00AM	Advanced Cell-based Therapy Booming the Success for Healthcare Sector (PR Newswire)
Mar-08-26 12:57PM	Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway (Insider Monkey)
Mar-03-26 09:15AM	Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -9.23%
08:00AM	Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-25-26 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.83%
Feb-11-26 05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Jan-07-26 08:00AM	Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +9.19%
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-31-25 11:12AM	LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases (Insider Monkey)
Dec-30-25 11:45PM	Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data (Insider Monkey)
08:05AM	Loading…
Dec-07-25 08:05AM	Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease (GlobeNewswire)
Nov-25-25 08:00AM	Prime Medicine to Present at 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-11-25 08:00AM	Prime Medicine to Present at Jefferies Global Healthcare Conference (GlobeNewswire) +11.21%
Nov-07-25 10:21AM	CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.85%
08:10AM	Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 08:01AM	Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (GlobeNewswire) -7.69%
Oct-30-25 04:01PM	Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy (GlobeNewswire) +13.56%
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV) +9.88%
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 04:50PM	Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?) (Barchart) +16.46%
Aug-26-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 09:10AM	Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -9.58%
08:00AM	Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-25 04:01PM	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.02% +11.39%
Jul-31-25 11:40PM	JonesTrading Maintains a Buy on Prime Medicine (PRME) (Insider Monkey)
Jul-30-25 09:33PM	Prime Medicine Announces Pricing of Public Offering (GlobeNewswire)
04:01PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:55AM	Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-20-25 12:35AM	BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT (Insider Monkey)
Jul-16-25 08:10AM	Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy (Business Wire) -5.83%
07:00AM	Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis (GlobeNewswire)
Jul-07-25 12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com) +22.19%
Jul-06-25 04:01AM	Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data (Insider Monkey)
May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)

Show Previous News

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

M.P.A.Mr. Jeffrey D. Marrazzo M.B.A.

CEO & DirectorDr. Allan Reine M.D.

Chief Technical OfficerDr. Ann L. Lee Ph.D.

Ph.D.Dr. Andrew Anzalone M.D.

Co-Founder & Member of Scientific Advisory BoardDr. David R. Liu Ph.D.

CTY

City Therapeutics Inc

PRME

Prime Medicine Inc

Upgrade your Finviz experience